October 7, 2021
November 12, 2019
April 28, 2020
January 20, 2021
June 9, 2022
Friends of Cancer Research (Friends) applauds the thoughtful work in constructing the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2022 – and particularly for including it in the Senate HELP user fee reauthorization bill (The FDA Safety and Landmark Advancements (FDASLA) Act). Diagnostic tests continue to be a growing component of cancer research and patient…
Learn MoreMay 26, 2022
A new analysis conducted by Friends of Cancer Research (Friends) published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, reveals that U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) criteria select drugs that lead to better outcomes for patients with lung cancer. The study titled “Breakthrough Therapy…
Learn MoreMay 18, 2022
Friends of Cancer Research (Friends) is encouraged by the notable progress being made within the House and Senate on the upcoming reauthorization of the FDA user fee programs. Representative Pallone and Representative McMorris-Rogers’s bill in the House as well as Senator Murray and Senators Burr’s newly released legislation in the Senate both support FDA programs to…
Learn MoreApril 4, 2022
Friends of Cancer Research (Friends) would like to thank Dr. Ned Sharpless for his tireless public service and scientific leadership as Director of the National Cancer Institute (NCI) as well as his tenure as acting Commissioner of the U.S. Food and Drug Administration (FDA). “Dr. Sharpless deserves our country’s deep gratitude for his years of…
Learn MoreFebruary 23, 2022
Friends of Cancer Research (Friends) would like to thank Dr. Janet Woodcock for serving as Acting Commissioner of the Food and Drug Administration (FDA) and is looking forward to working with Dr. Woodcock as Principal Deputy Commissioner of the Agency. The FDA has significant work in the months ahead to navigate ongoing actions related to…
Learn MoreFebruary 15, 2022
Friends of Cancer Research (Friends) would like to congratulate Dr. Robert Califf on his bipartisan confirmation today as FDA Commissioner. The United States is at a pivotal moment for public health, and the leadership Dr. Califf will bring to the FDA will be paramount to assuring the safety, effectiveness, and security of human drugs, and…
Learn MoreFebruary 2, 2022
Friends of Cancer Research (Friends) would like to congratulate President Biden and Dr. Biden on the announcement of a new Cancer Moonshot. We applaud the ambitious new goals and objectives that will be instrumental in changing the trajectory of cancer care and treatment and ending cancer as we know it today. We strongly support the…
Learn MoreJanuary 27, 2022
Friends of Cancer Research (Friends) is excited to announce its latest publication “Homologous Recombination Deficiency: Concepts, Definitions, and Assays.” Findings from this manuscript set the foundation for the ongoing Homologous Recombination Deficiency (HRD) Harmonization Project, a unique research partnership focused on developing strategies to assess assay performance and align on methods for measuring and using…
Learn MoreOctober 7, 2021
Washington, DC – Friends of Cancer Research (Friends) is pleased to announce findings from the final analysis of our TMB Harmonization Project published this week in Annals of Oncology, “Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.” Tumor mutational burden, or TMB, is…
Learn MoreJune 22, 2021
New ASCO-Friends Joint Position Statement Encourages Enrollment of Patients with Cancer in Vaccine Studies Alexandria, Va. and Washington, DC. – Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research…
Learn More